140 related articles for article (PubMed ID: 21382702)
1. A prognostic model to identify patients with advanced pancreas adenocarcinoma who could benefit from second-line chemotherapy.
Kim ST; Choi YJ; Park KH; Oh SC; Seo JH; Shin SW; Kim JS; Kim YH
Clin Oncol (R Coll Radiol); 2012 Mar; 24(2):105-11. PubMed ID: 21382702
[TBL] [Abstract][Full Text] [Related]
2. Selection of a patient subgroup with advanced esophageal squamous carcinoma who could benefit from second-line chemotherapy.
Kim ST; Park KH; Oh SC; Seo JH; Shin SW; Kim JS; Kim YH
Oncology; 2010; 79(5-6):363-9. PubMed ID: 21430405
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy.
Kim JG; Ryoo BY; Park YH; Kim BS; Kim TY; Im YH; Kang YK
Cancer Chemother Pharmacol; 2008 Feb; 61(2):301-7. PubMed ID: 17429626
[TBL] [Abstract][Full Text] [Related]
4. Performance status is an important prognostic factor in second line treatment of pancreaticobiliary adenocarcinoma.
Erdogan B; Turkmen E; Uzunoglu S; Tanriverdi O; Cicin I
Hepatogastroenterology; 2013 Sep; 60(126):1479-83. PubMed ID: 23933941
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors in patients treated with taxane-based chemotherapy for recurrent or metastatic endometrial cancer: proposal for a new prognostic model.
Mountzios G; Bamias A; Voulgaris Z; Rodolakis A; Vlahos G; Gourgoulis G; Papaiakovou EE; Giannopoulos A
Gynecol Oncol; 2008 Jan; 108(1):130-5. PubMed ID: 17988722
[TBL] [Abstract][Full Text] [Related]
6. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Aamdal S;
Lung Cancer; 2005 May; 48(2):251-61. PubMed ID: 15829326
[TBL] [Abstract][Full Text] [Related]
7. Response to second-line chemotherapy in patients with metastatic breast carcinoma previously responsive to first-line treatment: prognostic factors.
Brun B; Benchalal M; Lebas C; Piedbois P; Lin M; Lebourgeois JP
Cancer; 1997 Jun; 79(11):2137-46. PubMed ID: 9179060
[TBL] [Abstract][Full Text] [Related]
8. Optimal indications for second-line chemotherapy in advanced gastric cancer.
Hasegawa H; Fujitani K; Nakazuru S; Hirao M; Mita E; Tsujinaka T
Anticancer Drugs; 2012 Apr; 23(4):465-70. PubMed ID: 22227714
[TBL] [Abstract][Full Text] [Related]
9. Performance status and sensitivity to first-line chemotherapy are significant prognostic factors in patients with recurrent small cell lung cancer receiving second-line chemotherapy.
Kim YH; Goto K; Yoh K; Niho S; Ohmatsu H; Kubota K; Saijo N; Nishiwaki Y
Cancer; 2008 Nov; 113(9):2518-23. PubMed ID: 18780323
[TBL] [Abstract][Full Text] [Related]
10. Is chemotherapy in elderly patients with metastatic or recurrent gastric cancer as tolerable and effective as in younger patients?
Kim ST; Park KH; Oh SC; Seo JH; Shin SW; Kim JS; Kim YH
Asia Pac J Clin Oncol; 2012 Jun; 8(2):194-200. PubMed ID: 22524579
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck.
Argiris A; Li Y; Forastiere A
Cancer; 2004 Nov; 101(10):2222-9. PubMed ID: 15452834
[TBL] [Abstract][Full Text] [Related]
12. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies.
Huguet F; André T; Hammel P; Artru P; Balosso J; Selle F; Deniaud-Alexandre E; Ruszniewski P; Touboul E; Labianca R; de Gramont A; Louvet C
J Clin Oncol; 2007 Jan; 25(3):326-31. PubMed ID: 17235048
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors and predictive model in patients with advanced biliary tract adenocarcinoma receiving first-line palliative chemotherapy.
Park I; Lee JL; Ryu MH; Kim TW; Sook Lee S; Hyun Park D; Soo Lee S; Wan Seo D; Koo Lee S; Kim MH
Cancer; 2009 Sep; 115(18):4148-55. PubMed ID: 19536892
[TBL] [Abstract][Full Text] [Related]
14. The outcome of advanced or recurrent non-squamous carcinoma of the uterine cervix after platinum-based combination chemotherapy.
Kastritis E; Bamias A; Efstathiou E; Gika D; Bozas G; Zorzou P; Sarris K; Papadimitriou C; Dimopoulos MA
Gynecol Oncol; 2005 Nov; 99(2):376-82. PubMed ID: 16051322
[TBL] [Abstract][Full Text] [Related]
15. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
[TBL] [Abstract][Full Text] [Related]
16. Second-line chemotherapy with biweekly paclitaxel after failure of fluoropyrimidine-based treatment in patients with advanced or recurrent gastric cancer: a report from the gastrointestinal oncology group of the Tokyo cooperative oncology group, TCOG GC-0501 trial.
Koizumi W; Akiya T; Sato A; Yamaguchi K; Sakuyama T; Nakayama N; Tanabe S; Higuchi K; Sasaki T; Sekikawa T;
Jpn J Clin Oncol; 2009 Nov; 39(11):713-9. PubMed ID: 19812061
[TBL] [Abstract][Full Text] [Related]
17. Oxaliplatin, 5-fluorouracil, and leucovorin as second-line treatment for advanced pancreatic cancer.
Novarino A; Satolli MA; Chiappino I; Giacobino A; Bellone G; Rahimi F; Milanesi E; Bertetto O; Ciuffreda L
Am J Clin Oncol; 2009 Feb; 32(1):44-8. PubMed ID: 19194124
[TBL] [Abstract][Full Text] [Related]
18. Risk factors in germ cell tumour patients with relapse or progressive disease after first-line chemotherapy: evaluation of a prognostic score for survival after high-dose chemotherapy.
Sammler C; Beyer J; Bokemeyer C; Hartmann JT; Rick O
Eur J Cancer; 2008 Jan; 44(2):237-43. PubMed ID: 18055194
[TBL] [Abstract][Full Text] [Related]
19. Transplantation as salvage therapy for high-risk patients with myeloma in relapse.
Lee CK; Barlogie B; Zangari M; Fassas A; Anaissie E; Morris C; Van Rhee F; Cottler-Fox M; Thertulien R; Muwalla F; Mazher S; Badros A; Tricot G
Bone Marrow Transplant; 2002 Dec; 30(12):873-8. PubMed ID: 12476279
[TBL] [Abstract][Full Text] [Related]
20. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]